51
|
Yang Y, Yu Y, Chen H, Meng X, Ma W, Yu M, Li Z, Li C, Liu H, Zhang X, Xiao H, Yu Z. Illuminating Platinum Transportation while Maximizing Therapeutic Efficacy by Gold Nanoclusters via Simultaneous Near-Infrared-I/II Imaging and Glutathione Scavenging. ACS NANO 2020; 14:13536-13547. [PMID: 32924505 DOI: 10.1021/acsnano.0c05541] [Citation(s) in RCA: 143] [Impact Index Per Article: 35.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Killing tumor cells with a visualized system is a promising strategy in tumor therapy to achieve minimal side effects and high efficiency. Herein, a theranostic nanomedicine (AuNCs-Pt) is developed based on nanocarrier gold nanoclusters (AuNCs) with bifunctions of both NIR-I/NIR-II imaging and glutathione-scavenging abilities. AuNCs-Pt possesses NIR-II imaging capability on a fatal high-grade serous ovarian cancer (HGSOC) model in the deep abdomen, thus facilitating it to be a promising tool for monitoring platinum transportation. Meanwhile, AuNCs-Pt depletes intracellular glutathione to minimize platinum detoxification, effectively maximizing the chemotherapeutic efficacy of platinum. AuNCs-Pt is used to eradicate the tumor burden in this study on a HGSOC model and a patient-derived tumor xenograft model of hepatocellular carcinoma, suggesting great potential for clinical visualized therapy and platinum drug sensitization.
Collapse
Affiliation(s)
- Yuanyuan Yang
- Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, No. 1023, South Shatai Road, Guangzhou 510515, China
| | - Yingjie Yu
- Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, No. 1023, South Shatai Road, Guangzhou 510515, China
- Beijing National Laboratory for Molecular Sciences, State Key Laboratory of Polymer Physics and Chemistry Institute of Chemistry, Chinese Academy of Sciences, No. 2, Zhongguancun Road, Beijing 100190, China
| | - Hao Chen
- Beijing Laboratory of Biomedical Materials, Beijing University of Chemical Technology, No. 15, North Third Ring Road, Beijing 100029, China
| | - Xiangxi Meng
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, No. 52, Fucheng Road, Beijing 100142, China
| | - Wen Ma
- Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, No. 1023, South Shatai Road, Guangzhou 510515, China
| | - Meng Yu
- Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, No. 1023, South Shatai Road, Guangzhou 510515, China
| | - Ziyuan Li
- Department of Biomedical Engineering, College of Engineering, Peking University, No. 5, Yiheyuan Road, Beijing 100871, China
| | - Changhui Li
- Department of Biomedical Engineering, College of Engineering, Peking University, No. 5, Yiheyuan Road, Beijing 100871, China
| | - Haile Liu
- Department of Physics and Tianjin Key Laboratory of Low Dimensional Materials Physics and Preparing Technology, School of Science, Tianjin University, No. 135, Yaguan Road, Tianjin 300354, China
| | - Xiaodong Zhang
- Department of Physics and Tianjin Key Laboratory of Low Dimensional Materials Physics and Preparing Technology, School of Science, Tianjin University, No. 135, Yaguan Road, Tianjin 300354, China
| | - Haihua Xiao
- Beijing National Laboratory for Molecular Sciences, State Key Laboratory of Polymer Physics and Chemistry Institute of Chemistry, Chinese Academy of Sciences, No. 2, Zhongguancun Road, Beijing 100190, China
| | - Zhiqiang Yu
- Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, No. 1023, South Shatai Road, Guangzhou 510515, China
| |
Collapse
|
52
|
Shukla S, Hu H, Cai H, Chan SK, Boone CE, Beiss V, Chariou PL, Steinmetz NF. Plant Viruses and Bacteriophage-Based Reagents for Diagnosis and Therapy. Annu Rev Virol 2020; 7:559-587. [PMID: 32991265 PMCID: PMC8018517 DOI: 10.1146/annurev-virology-010720-052252] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Viral nanotechnology exploits the prefabricated nanostructures of viruses, which are already abundant in nature. With well-defined molecular architectures, viral nanocarriers offer unprecedented opportunities for precise structural and functional manipulation using genetic engineering and/or bio-orthogonal chemistries. In this manner, they can be loaded with diverse molecular payloads for targeted delivery. Mammalian viruses are already established in the clinic for gene therapy and immunotherapy, and inactivated viruses or virus-like particles have long been used as vaccines. More recently, plant viruses and bacteriophages have been developed as nanocarriers for diagnostic imaging, vaccine and drug delivery, and combined diagnosis/therapy (theranostics). The first wave of these novel virus-based tools has completed clinical development and is poised to make an impact on clinical practice.
Collapse
Affiliation(s)
- Sourabh Shukla
- Department of NanoEngineering, University of California, San Diego, La Jolla, California 92093, USA
| | - He Hu
- Department of NanoEngineering, University of California, San Diego, La Jolla, California 92093, USA
| | - Hui Cai
- Department of NanoEngineering, University of California, San Diego, La Jolla, California 92093, USA
| | - Soo-Khim Chan
- Department of NanoEngineering, University of California, San Diego, La Jolla, California 92093, USA
| | - Christine E Boone
- Department of NanoEngineering, University of California, San Diego, La Jolla, California 92093, USA
| | - Veronique Beiss
- Department of NanoEngineering, University of California, San Diego, La Jolla, California 92093, USA
| | - Paul L Chariou
- Department of NanoEngineering, University of California, San Diego, La Jolla, California 92093, USA
| | - Nicole F Steinmetz
- Department of NanoEngineering, University of California, San Diego, La Jolla, California 92093, USA
- Department of Radiology, University of California, San Diego, La Jolla, California 92093, USA
- Department of Bioengineering, University of California, San Diego, La Jolla, California 92093, USA
- Moores Cancer Center and Center for Nano-ImmunoEngineering, University of California, San Diego, La Jolla, California 92093, USA;
| |
Collapse
|
53
|
Phelps DL, Saso S, Ghaem-Maghami S. Is ovarian cancer surgery stuck in the dark ages?: a commentary piece reviewing surgical technologies. Br J Cancer 2020; 123:1471-1473. [PMID: 32830203 PMCID: PMC7652870 DOI: 10.1038/s41416-020-01035-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2020] [Revised: 07/20/2020] [Accepted: 08/06/2020] [Indexed: 11/09/2022] Open
Abstract
Ovarian cancer surgery endeavours to remove all visible tumour deposits, and surgical technologies could potentially facilitate this aim. However, there appear to be barriers around the adoption of new technologies, and we hope this article provokes discussion within the specialty to encourage a forward-thinking approach to new-age surgical gynaecological oncology.
Collapse
Affiliation(s)
- David L Phelps
- Imperial College Healthcare NHS Trust, London, W12 0HS, UK
| | - Srdjan Saso
- Imperial College Healthcare NHS Trust, London, W12 0HS, UK
| | | |
Collapse
|
54
|
Fung K, Sharma SK, Keinänen O, Roche KL, Lewis JS, Zeglis BM. A Molecularly Targeted Intraoperative Near-Infrared Fluorescence Imaging Agent for High-Grade Serous Ovarian Cancer. Mol Pharm 2020; 17:3140-3147. [PMID: 32644804 DOI: 10.1021/acs.molpharmaceut.0c00437] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Ovarian cancer is the fifth leading cause of cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. The foundation of its management consists of cytoreductive surgery (CRS) followed by systemic chemotherapy, with the completeness of surgical resection consistently identified as one of the most important prognostic factors for the disease. The goal of our investigation is the development of a near-infrared fluorescence (NIRF) imaging agent for the intraoperative imaging of high-grade serous ovarian cancer (HGSOC). As surgeons are currently limited to the visual and manual assessment of tumor tissue during CRS, this technology could facilitate more complete resections as well as serve important functions at other points in the surgical management of the disease. Elevated levels of cancer antigen 125 (CA125) have proven a useful biomarker of HGSOC, and the CA125-targeting antibody B43.13 has shown potential as a platform for immunoPET imaging in murine models of ovarian cancer. Herein, we report the development of a NIRF imaging agent based on B43.13: ssB43.13-IR800. We site-specifically modified the heavy chain glycans of B43.13 with the near-infrared dye IRDye 800CW using a chemoenzymatic approach developed in our laboratories. SDS-PAGE analysis confirmed the specificity of the conjugation reaction, and flow cytometry, immunostaining, and fluorescence microscopy verified the specific binding of ssB43.13-IR800 to CA125-expressing OVCAR3 human ovarian cancer cells. NIRF imaging studies demonstrated that ssB43.13-IR800 can be used to image CA125-expressing HGSOC tumors in subcutaneous, orthotopic, and patient-derived xenograft mouse models. Finally, ex vivo analyses confirmed that ssB43.13-IR800 can bind and identify CA125-expressing cells in primary tumor and metastatic lymph node samples from human patients with HGSOC.
Collapse
Affiliation(s)
- Kimberly Fung
- Department of Chemistry, Hunter College, City University of New York, New York, New York 10021, United States.,Ph.D. Program in Chemistry, The Graduate Center of the City University of New York, New York, New York 10016, United States
| | | | - Outi Keinänen
- Department of Chemistry, Hunter College, City University of New York, New York, New York 10021, United States
| | - Kara Long Roche
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States
| | | | - Brian M Zeglis
- Department of Chemistry, Hunter College, City University of New York, New York, New York 10021, United States.,Ph.D. Program in Chemistry, The Graduate Center of the City University of New York, New York, New York 10016, United States
| |
Collapse
|
55
|
Kleinmanns K, Fosse V, Davidson B, de Jalón EG, Tenstad O, Bjørge L, McCormack E. CD24-targeted intraoperative fluorescence image-guided surgery leads to improved cytoreduction of ovarian cancer in a preclinical orthotopic surgical model. EBioMedicine 2020; 56:102783. [PMID: 32454402 PMCID: PMC7248677 DOI: 10.1016/j.ebiom.2020.102783] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2020] [Revised: 04/03/2020] [Accepted: 04/21/2020] [Indexed: 02/09/2023] Open
Abstract
BACKGROUND The completeness of resection is a key prognostic indicator in patients with ovarian cancer, and the application of tumour-targeted fluorescence image-guided surgery (FIGS) has led to improved detection of peritoneal metastases during cytoreductive surgery. CD24 is highly expressed in ovarian cancer and has been shown to be a suitable biomarker for tumour-targeted imaging. METHODS CD24 expression was investigated in cell lines and heterogenous patient-derived xenograft (PDX) tumour samples of high-grade serous ovarian carcinoma (HGSOC). After conjugation of the monoclonal antibody CD24 to the NIR dye Alexa Fluor 750 and the evaluation of the optimal pharmacological parameters (OV-90, n = 21), orthotopic HGSOC metastatic xenografts (OV-90, n = 16) underwent cytoreductive surgery with real-time feedback. The impact of intraoperative CD24-targeted fluorescence guidance was compared to white light and palpation alone, and the recurrence of disease was monitored post-operatively (OV-90, n = 12). CD24-AF750 was further evaluated in four clinically annotated orthotopic PDX models of metastatic HGSOC, to validate the translational potential for intraoperative guidance. FINDINGS CD24-targeted intraoperative NIR FIGS significantly (47•3%) improved tumour detection and resection, and reduced the post-operative tumour burden compared to standard white-light surgery in orthotopic HGSOC xenografts. CD24-AF750 allowed identification of minuscule tumour lesions which were undetectable with the naked eye in four HGSOC PDX. INTERPRETATION CD24-targeted FIGS has translational potential as an aid to improve debulking surgery of ovarian cancer. FUNDING This study was supported by the H2020 program MSCA-ITN [675743], Helse Vest RHF, and Helse Bergen HF [911809, 911852, 912171, 240222, 911974, HV1269], as well as by The Norwegian Cancer Society [182735], and The Research Council of Norway through its Centres of excellence funding scheme [223250, 262652].
Collapse
Affiliation(s)
- Katrin Kleinmanns
- Center for Cancer Biomarkers, CCBIO, Department of Clinical Science, University of Bergen, Jonas Lies vei 91B, 5021 Bergen, Norway
| | - Vibeke Fosse
- Center for Cancer Biomarkers, CCBIO, Department of Clinical Science, University of Bergen, Jonas Lies vei 91B, 5021 Bergen, Norway; Department of Radiology, Erasmus Medical Centre, 3000 CA Rotterdam, the Netherlands
| | - Ben Davidson
- Department of Pathology, Oslo University Hospital, Norwegian Radium Hospital, 0310 Oslo, Norway; Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, 0316 Oslo, Norway
| | - Elvira García de Jalón
- Center for Cancer Biomarkers, CCBIO, Department of Clinical Science, University of Bergen, Jonas Lies vei 91B, 5021 Bergen, Norway; Department of Chemistry and Centre for Pharmacy, University of Bergen, Allégaten 41, 5007 Bergen, Norway
| | - Olav Tenstad
- Department of Biomedicine, University of Bergen, Jonas Lies vei 91B, 5021 Bergen, Norway
| | - Line Bjørge
- Center for Cancer Biomarkers, CCBIO, Department of Clinical Science, University of Bergen, Jonas Lies vei 91B, 5021 Bergen, Norway; Department of Obstetrics and Gyneacology, Haukeland University Hospital, 5021 Bergen, Norway
| | - Emmet McCormack
- Center for Cancer Biomarkers, CCBIO, Department of Clinical Science, University of Bergen, Jonas Lies vei 91B, 5021 Bergen, Norway.
| |
Collapse
|
56
|
Arend R, Martinez A, Szul T, Birrer MJ. Biomarkers in ovarian cancer: To be or not to be. Cancer 2020; 125 Suppl 24:4563-4572. [PMID: 31967683 DOI: 10.1002/cncr.32595] [Citation(s) in RCA: 34] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2019] [Accepted: 08/15/2019] [Indexed: 11/09/2022]
Abstract
Biomarkers are becoming increasingly important in the treatment of epithelial ovarian cancer. Recent work from many laboratories has begun to provide clinically meaningful biomarkers. This review summarizes the state of the science regarding biomarkers for stratifying early-stage patients into those who benefit from adjuvant treatment, primary debulking versus interval debulking, and specific targeted therapy. In addition, new molecular imaging technologies have been developed to allow the surgeon to resect subvisible tumor deposits. These efforts should increase clinical effectiveness while minimizing toxicities for patients.
Collapse
Affiliation(s)
- Rebecca Arend
- University of Alabama at Birmingham, Birmingham, Alabama
| | - Alba Martinez
- University of Alabama at Birmingham, Birmingham, Alabama
| | - Tomasz Szul
- University of Alabama at Birmingham, Birmingham, Alabama
| | | |
Collapse
|
57
|
CD24-targeted fluorescence imaging in patient-derived xenograft models of high-grade serous ovarian carcinoma. EBioMedicine 2020; 56:102782. [PMID: 32454401 PMCID: PMC7248428 DOI: 10.1016/j.ebiom.2020.102782] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2019] [Revised: 04/02/2020] [Accepted: 04/21/2020] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND The survival rate of patients with advanced high-grade serous ovarian carcinoma (HGSOC) remains disappointing. Clinically translatable orthotopic cell line xenograft models and patient-derived xenografts (PDXs) may aid the implementation of more personalised treatment approaches. Although orthotopic PDX reflecting heterogeneous molecular subtypes are considered the most relevant preclinical models, their use in therapeutic development is limited by lack of appropriate imaging modalities. METHODS We developed novel orthotopic xenograft and PDX models for HGSOC, and applied a near-infrared fluorescently labelled monoclonal antibody targeting the cell surface antigen CD24 for non-invasive molecular imaging of epithelial ovarian cancer. CD24-Alexa Fluor 680 fluorescence imaging was compared to bioluminescence imaging in three orthotopic cell line xenograft models of ovarian cancer (OV-90luc+, Skov-3luc+ and Caov-3luc+, n = 3 per model). The application of fluorescence imaging to assess treatment efficacy was performed in carboplatin-paclitaxel treated orthotopic OV-90 xenografts (n = 10), before the probe was evaluated to detect disease progression in heterogenous PDX models (n = 7). FINDINGS Application of the near-infrared probe, CD24-AF680, enabled both spatio-temporal visualisation of tumour development, and longitudinal therapy monitoring of orthotopic xenografts. Notably, CD24-AF680 facilitated imaging of multiple PDX models representing different histological subtypes of the disease. INTERPRETATION The combined implementation of CD24-AF680 and orthotopic PDX models creates a state-of-the-art preclinical platform which will impact the identification and validation of new targeted therapies, fluorescence image-guided surgery, and ultimately the outcome for HGSOC patients. FUNDING This study was supported by the H2020 program MSCA-ITN [675743], Helse Vest RHF, and Helse Bergen HF [911809, 911852, 912171, 240222, HV1269], as well as by The Norwegian Cancer Society [182735], and The Research Council of Norway through its Centers of excellence funding scheme [223250, 262652].
Collapse
|
58
|
Quicker, deeper and stronger imaging: A review of tumor-targeted, near-infrared fluorescent dyes for fluorescence guided surgery in the preclinical and clinical stages. Eur J Pharm Biopharm 2020; 152:123-143. [PMID: 32437752 DOI: 10.1016/j.ejpb.2020.05.002] [Citation(s) in RCA: 31] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2019] [Revised: 05/03/2020] [Accepted: 05/03/2020] [Indexed: 12/12/2022]
Abstract
Cancer is a public health problem and the main cause of human mortality and morbidity worldwide. Complete removal of tumors and metastatic lymph nodes in surgery is significantly beneficial for the prognosis of patients. Tumor-targeted, near-infrared fluorescent (NIRF) imaging is an emerging field of real-time intraoperative cancer imaging based on tumor-targeted NIRF dyes. Targeted NIRF dyes contain NIRF fluorophores and specific binding ligands such as antibodies, peptides and small molecules. The present article reviews recently updated tumor-targeted NIRF dyes for the molecular imaging of malignant tumors in the preclinical stage and clinical trials. The strengths and challenges of NIRF agents with tumor-targeting ability are also summarized. Smaller ligands, near infrared II dyes, dual-modality dyes and activatable dyes may contribute to quicker, deeper, stronger imaging in the nearest future. In this review, we highlighted tumor-targeted NIRF dyes for fluorescence-guided surgery and their potential clinical translation.
Collapse
|
59
|
Cazier H, Malgorn C, Fresneau N, Georgin D, Sallustrau A, Chollet C, Tabet JC, Campidelli S, Pinault M, Mayne M, Taran F, Dive V, Junot C, Fenaille F, Colsch B. Development of a Mass Spectrometry Imaging Method for Detecting and Mapping Graphene Oxide Nanoparticles in Rodent Tissues. JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY 2020; 31:1025-1036. [PMID: 32223237 DOI: 10.1021/jasms.9b00070] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
Graphene-based nanoparticles are continuously being developed for biomedical applications, and their use raises concerns about their environmental and biological impact. In the literature, some imaging techniques based on fluorescence and radioimaging have been used to explore their fate in vivo. Here, we report on the use of label-free mass spectrometry and mass spectrometry imaging (MSI) for graphene oxide (GO) and reduced graphene oxide (rGO) analyses in rodent tissues. Thereby, we extend previous work by focusing on practical questions to obtain reliable and meaningful images. Specific radical anionic carbon clusters ranging from C2-• to C9-• were observed for both GO and rGO species, with a base peak at m/z 72 under negative laser desorption ionization mass spectrometry (LDI-MS) conditions. Extension to an LDI-MSI method was then performed, thus enabling the efficient detection of GO nanoparticles in lung tissue sections of previously exposed mice. The possibility of quantifying those nanoparticles on tissue sections has also been investigated. Two different ways of building calibration curves (i.e., GO suspensions spotted on tissue sections, or added to lung tissue homogenates) were evaluated and returned similar results, with linear dynamic concentration ranges over at least 2 orders of magnitude. Moreover, intra- and inter-day precision studies have been assessed, with relative standard deviation below 25% for each concentration point of a calibration curve. In conclusion, our study confirms that LDI-MSI is a relevant approach for biodistribution studies of carbon-based nanoparticles, as quantification can be achieved, provided that nanoparticle suspension and manufacturing are carefully controlled.
Collapse
Affiliation(s)
- Hélène Cazier
- INRAE, Médicaments et Technologies pour la Santé (MTS), Université Paris-Saclay, CEA, 91191 Gif-sur-Yvette, France
| | - Carole Malgorn
- INRAE, Médicaments et Technologies pour la Santé (MTS), Université Paris-Saclay, CEA, 91191 Gif-sur-Yvette, France
| | - Nathalie Fresneau
- INRAE, Médicaments et Technologies pour la Santé (MTS), Université Paris-Saclay, CEA, 91191 Gif-sur-Yvette, France
| | - Dominique Georgin
- INRAE, Médicaments et Technologies pour la Santé (MTS), Université Paris-Saclay, CEA, 91191 Gif-sur-Yvette, France
| | - Antoine Sallustrau
- INRAE, Médicaments et Technologies pour la Santé (MTS), Université Paris-Saclay, CEA, 91191 Gif-sur-Yvette, France
| | - Céline Chollet
- INRAE, Médicaments et Technologies pour la Santé (MTS), Université Paris-Saclay, CEA, 91191 Gif-sur-Yvette, France
| | - Jean-Claude Tabet
- INRAE, Médicaments et Technologies pour la Santé (MTS), Université Paris-Saclay, CEA, 91191 Gif-sur-Yvette, France
| | | | - Mathieu Pinault
- INRAE, Médicaments et Technologies pour la Santé (MTS), Université Paris-Saclay, CEA, 91191 Gif-sur-Yvette, France
| | - Martine Mayne
- INRAE, Médicaments et Technologies pour la Santé (MTS), Université Paris-Saclay, CEA, 91191 Gif-sur-Yvette, France
| | - Frédéric Taran
- INRAE, Médicaments et Technologies pour la Santé (MTS), Université Paris-Saclay, CEA, 91191 Gif-sur-Yvette, France
| | - Vincent Dive
- INRAE, Médicaments et Technologies pour la Santé (MTS), Université Paris-Saclay, CEA, 91191 Gif-sur-Yvette, France
| | - Christophe Junot
- INRAE, Médicaments et Technologies pour la Santé (MTS), Université Paris-Saclay, CEA, 91191 Gif-sur-Yvette, France
| | - François Fenaille
- INRAE, Médicaments et Technologies pour la Santé (MTS), Université Paris-Saclay, CEA, 91191 Gif-sur-Yvette, France
| | - Benoit Colsch
- INRAE, Médicaments et Technologies pour la Santé (MTS), Université Paris-Saclay, CEA, 91191 Gif-sur-Yvette, France
| |
Collapse
|
60
|
Wojtynek NE, Mohs AM. Image-guided tumor surgery: The emerging role of nanotechnology. WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY 2020; 12:e1624. [PMID: 32162485 DOI: 10.1002/wnan.1624] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/20/2019] [Revised: 02/12/2020] [Accepted: 02/14/2020] [Indexed: 12/15/2022]
Abstract
Surgical resection is a mainstay treatment for solid tumors. Yet, methods to distinguish malignant from healthy tissue are primarily limited to tactile and visual cues as well as the surgeon's experience. As a result, there is a possibility that a positive surgical margin (PSM) or the presence of residual tumor left behind after resection may occur. It is well-documented that PSMs can negatively impact treatment outcomes and survival, as well as pose an economic burden. Therefore, surgical tumor imaging techniques have emerged as a promising method to decrease PSM rates. Nanoparticles (NPs) have unique characteristics to serve as optical contrast agents during image-guided surgery (IGS). Recently, there has been tremendous growth in the volume and types of NPs used for IGS, including clinical trials. Herein, we describe the most recent contributions of nanotechnology for surgical tumor identification. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Implantable Materials and Surgical Technologies > Nanoscale Tools and Techniques in Surgery Diagnostic Tools > in vivo Nanodiagnostics and Imaging.
Collapse
Affiliation(s)
- Nicholas E Wojtynek
- Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska.,Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska
| | - Aaron M Mohs
- Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska.,Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska.,Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska.,Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, Omaha, Nebraska
| |
Collapse
|
61
|
Heller DA, Jena PV, Pasquali M, Kostarelos K, Delogu LG, Meidl RE, Rotkin SV, Scheinberg DA, Schwartz RE, Terrones M, Wang Y, Bianco A, Boghossian AA, Cambré S, Cognet L, Corrie SR, Demokritou P, Giordani S, Hertel T, Ignatova T, Islam MF, Iverson NM, Jagota A, Janas D, Kono J, Kruss S, Landry MP, Li Y, Martel R, Maruyama S, Naumov AV, Prato M, Quinn SJ, Roxbury D, Strano MS, Tour JM, Weisman RB, Wenseleers W, Yudasaka M. Banning carbon nanotubes would be scientifically unjustified and damaging to innovation. NATURE NANOTECHNOLOGY 2020; 15:164-166. [PMID: 32157238 PMCID: PMC10461884 DOI: 10.1038/s41565-020-0656-y] [Citation(s) in RCA: 50] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
Affiliation(s)
- Daniel A Heller
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA.
| | - Prakrit V Jena
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Matteo Pasquali
- Department of Chemical & Biomolecular Engineering, Rice University, Houston, TX, USA
- Department of Chemistry, Rice University, Houston, TX, USA
- Department of Materials Science and Nanoengineering, Rice University, Houston, TX, USA
| | - Kostas Kostarelos
- Nanomedicine Lab, The University of Manchester, Manchester, UK
- Catalan Institute of Nanoscience and Nanotechnology (ICN2), Barcelona, Spain
| | - Lucia G Delogu
- Department of Biomedical Sciences, University of Padua, Padua, Italy
| | - Rachel E Meidl
- Baker Institute for Public Policy, Rice University, Houston, TX, USA
| | - Slava V Rotkin
- Department of Engineering Science & Mechanics, The Pennsylvania State University, University Park, PA, USA
- Materials Research Institute, The Pennsylvania State University, University Park, PA, USA
| | - David A Scheinberg
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA
- Department of Medicine, Weill Cornell Medicine, New York, NY, USA
| | - Robert E Schwartz
- Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA
| | - Mauricio Terrones
- Department of Physics, The Pennsylvania State University, University Park, PA, USA
| | - YuHuang Wang
- Department of Chemistry and Biochemistry, University of Maryland, College Park, MD, USA
| | - Alberto Bianco
- CNRS, UPR3572, Immunology, Immunopathology and Therapeutic Chemistry, University of Strasbourg, ISIS, Strasbourg, France
| | - Ardemis A Boghossian
- Institute of Chemical Sciences and Engineering (ISIC), Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - Sofie Cambré
- Department of Physics, University of Antwerp, Antwerp, Belgium
| | - Laurent Cognet
- Laboratoire Photonique Numérique et Nanosciences, University of Bordeaux, Talence, France
| | - Simon R Corrie
- Department of Chemical Engineering, Monash University, Clayton, Victoria, Australia
| | - Philip Demokritou
- Center for Nanotechnology and Nanotoxicology, Department of Environmental Health, Harvard T. H. Chan School of Public Health, Harvard University, Boston, MA, USA
| | - Silvia Giordani
- School of Chemical Sciences, Dublin City University, Dublin, Ireland
| | - Tobias Hertel
- Institute of Physical and Theoretical Chemistry, Julius-Maximilians University Würzburg, Würzburg, Germany
| | - Tetyana Ignatova
- Nanoscience Department, University of North Carolina at Greensboro, Greensboro, NC, USA
| | - Mohammad F Islam
- Department of Materials Science & Engineering, Carnegie Mellon University, Pittsburgh, PA, USA
| | - Nicole M Iverson
- Department of Biological Systems Engineering, University of Nebraska-Lincoln, Lincoln, NE, USA
| | - Anand Jagota
- Department of Bioengineering, Lehigh University, Bethlehem, PA, USA
| | - Dawid Janas
- Department of Chemistry, Silesian University of Technology, Gliwice, Poland
| | - Junichiro Kono
- Department of Materials Science and Nanoengineering, Rice University, Houston, TX, USA
- Department of Electrical and Computer Engineering, Rice University, Houston, TX, USA
- Department of Physics and Astronomy, Rice University, Houston, TX, USA
| | - Sebastian Kruss
- Department of Chemistry, Georg-August-Universität Göttingen, Göttingen, Germany
| | - Markita P Landry
- Department of Chemical and Biomolecular Engineering, University of California, Berkeley, CA, USA
| | - Yan Li
- College of Chemistry and Molecular Engineering, Peking University, Beijing, China
| | - Richard Martel
- Département de chimie, Université de Montréal, Montréal, Quebec, Canada
| | - Shigeo Maruyama
- Department of Mechanical Engineering, The University of Tokyo, Tokyo, Japan
| | - Anton V Naumov
- Department of Physics and Astronomy, Texas Christian University, Fort Worth, TX, USA
| | - Maurizio Prato
- Dipartimento di Scienze Chimiche e Farmaceutiche, University of Trieste, Trieste, Italy
- Carbon Bionanotechnology Lab, CIC biomaGUNE, San Sebastián, Spain
- Ikerbasque, Basque Foundation for Science, Bilbao, Spain
| | - Susan J Quinn
- School of Chemistry, University College Dublin, Dublin, Ireland
| | - Daniel Roxbury
- Department of Chemical Engineering, University of Rhode Island, Kingston, RI, USA
| | - Michael S Strano
- Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA
| | - James M Tour
- Department of Chemistry, Rice University, Houston, TX, USA
- Department of Materials Science and Nanoengineering, Rice University, Houston, TX, USA
| | | | - Wim Wenseleers
- Department of Physics, University of Antwerp, Antwerp, Belgium
| | - Masako Yudasaka
- Nanomaterials Research Institute, Advanced Industrial Science and Technology (AIST), Tsukuba, Japan
| |
Collapse
|